Overview

Psychopharmacotherapy in Multiple Substances Abuse

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
Phase:
Phase 3
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborator:
National Institutes of Health (NIH)
Treatments:
Memantine